| September 11, 2024 |
Timely Disclosure Information
|
Notice Regarding Differences between Non-consolidated Results for Fiscal Year Ended July 31 2024 and those for Previous Fiscal Year
|
| August 9, 2024 |
Timely Disclosure Information
|
StemRIM Announces Fixed Details of the Issuance of Stock Options to Temporary Employees and External Collaborator
|
| August 8, 2024 |
Timely Disclosure Information
|
StemRIM Announces Patent Registration in China for Peripheral Peptides of the HMGB1 Fragment Peptide Redasemtide
|
| July 26, 2024 |
Timely Disclosure Information
|
StemRIM Announces Fixed Details of the Issuance of Stock Options to Directors
|
| July 26, 2024 |
Timely Disclosure Information
|
StemRIM Announces Fixed Details of the Issuance of Stock Options to Employees
|
| July 25, 2024 |
Timely Disclosure Information
|
StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Employees
|
| July 25, 2024 |
Timely Disclosure Information
|
StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Directors
|
| July 25, 2024 |
Timely Disclosure Information
|
StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Temporary Employees and External Collaborator
|
| July 8, 2024 |
Timely Disclosure Information
|
StemRIM Announces Patent Registration in Japan for Stem Cell & Gene Therapy for Dystrophic Epidermolysis Bullosa
|
| July 1, 2024 |
Timely Disclosure Information
|
Notice of Extraordinary General Meeting of Shareholders
|
| June 17, 2024 |
Timely Disclosure Information
|
StemRIM Announces Patent Registration (Australia) for the HMGB1 Fragment Peptide Redasemtide as an Additional Therapeutic Indication
|
| May 8, 2024 |
Timely Disclosure Information
|
StemRIM Announces Setting the Record Date for Extraordinary General Meeting of Shareholders, and Reduction of Capital Stock (Capital Decrease)
|
| March 21, 2024 |
Timely Disclosure Information
|
StemRIM Announces Symposium on “Regeneration-Induced Pluripotent Stem Cells” at the 23rd Congress of the Japanese Society for Regenerative Medicine
|
| March 13, 2024 |
Timely Disclosure Information
|
StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy
|
| February 29, 2024 |
Timely Disclosure Information
|
StemRIM Announces Fixed Details of the Issuance of Stock Options to External Collaborators
|
